Shares of Arena Pharmaceuticals (Nasdaq:ARNA) were gapping down Friday morning with an open price 10.1% lower than Thursday's closing price. The stock closed at $8.40 yesterday and opened today's trading at $7.55.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Shares of Arena Pharmaceuticals (Nasdaq: ARNA) were gapping down Friday morning with an open price 10.1% lower than Thursday's closing price. The stock closed at $8.40 Thursday and opened today's trading at $7.55.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The average volume for Arena has been 4.7 million shares per day over the past 30 days. Arena has a market cap of $1.79 billion and is part of the health care sector and drugs industry. Shares are down 8.8% year to date as of the close of trading on Thursday. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. TheStreet Ratings rates Arena as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth. You can view the full Arena Ratings Report. Get more investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.